99mTc‐labeled, tofacitinib citrate encapsulated chitosan microspheres loaded in situ gel formulations for intra‐articular treatment of rheumatoid arthritis

Abstract

AbstractInflammatory diseases including rheumatoid arthritis are major health problems. Although different techniques and drugs are clinically available for the diagnosis and therapy of the disease, novel approaches regarding radiolabeled drug delivery systems are researched. Hence, in the present study, it was aimed to design, prepare, and characterize 99mTc‐radiolabeled and tofacitinib citrate‐encapsulated microsphere loaded poloxamer in situ gel formulations for the intra‐articular treatment. Among nine different microsphere formulations, MS/TOFA‐9 was chosen as the most proper one due to particle size, high encapsulation efficiency, and in vitro drug release behavior. Poloxamer 338 at a concentration of 15% was used to prepare in situ gel formulations. For intra‐articular administration, microspheres were dispersed in an in situ gel containing 15% Poloxamer 338 and characterized in terms of gelation temperature, viscosity, rheological, mechanical, and spreadability properties. After the determination of the safe dose for MS/TOFA‐9 and PLX‐MS/TOFA‐9 as 40 µL/mL in the cell culture study performed on healthy cells, the high anti‐inflammatory effects were due to significant cellular inhibition of fibroblasts. In the radiolabeling studies with 99mTc, the optimum radiolabeling condition was determined as 200 ppm SnCl2 and 0.5 mg ascorbic acid, and both 99mTc‐MS/TOFA‐9 and 99mTc‐PLX‐MS/TOFA‐9 exhibited high cellular binding capacity. In conclusion, although further in vivo experiments are required, PLX‐MS/TOFA‐9 was found to be a promising agent for intra‐articular injection in rheumatoid arthritis.